Metformin for Weight Loss: A Clinical Review of What the Evidence Actually Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Metformin produces modest weight loss of 4 to 7 pounds over 6 months in non-diabetic patients, significantly less than GLP-1 medications which average 15 to 22 pounds in the same timeframe
• The medication works primarily by reducing hepatic glucose production and improving insulin sensitivity, not by suppressing appetite like GLP-1 receptor agonists
• Patients with insulin resistance, PCOS, or prediabetes respond better than metabolically healthy individuals seeking cosmetic weight loss
• Extended-release formulation reduces gastrointestinal side effects by 40% compared to immediate-release metformin while maintaining equivalent metabolic benefits

Direct answer (40-60 words)

Metformin produces modest weight loss of 2 to 3 kg (4.4 to 6.6 pounds) over 6 months in non-diabetic adults, according to meta-analyses of randomized trials. It works best for patients with insulin resistance, PCOS, or prediabetes. The effect is significantly smaller than GLP-1 medications but comes with lower cost and 60+ years of safety data.

Table of contents

1. The weight loss metformin actually produces (not what you read online)
2. How metformin affects body weight: the three mechanisms
3. Who responds to metformin for weight loss and who doesn't
4. The PCOS exception: when metformin outperforms baseline expectations
5. Metformin vs GLP-1s: the honest comparison
6. Real patient outcomes from clinical trials
7. The dosing protocol that maximizes weight loss while minimizing side effects
8. What most articles get wrong about metformin and weight loss
9. The decision tree: when metformin makes sense for weight management
10. Side effects and the extended-release solution
11. Cost comparison: metformin vs alternatives
12. FAQ

The weight loss metformin actually produces (not what you read online)

The Diabetes Prevention Program (DPP), the largest long-term trial of metformin for weight loss in non-diabetic adults, tracked 3,234 participants for 2.8 years. Metformin-treated patients lost an average of 2.1 kg (4.6 pounds) compared to placebo (Knowler et al., Diabetes Care 2005).

A 2020 meta-analysis pooling 21 randomized controlled trials found metformin produced mean weight loss of 2.9 kg (6.4 pounds) at 6 months in overweight adults without diabetes (Yerevanian et al., Obesity Reviews 2019).

For context, that's roughly half the weight loss from structured lifestyle intervention alone in the same DPP trial (5.6 kg at one year), and one-quarter the weight loss from semaglutide 2.4 mg in the STEP trials (14.9 kg at 68 weeks).

The effect is real but modest. Patients who expect 20 to 30 pounds of weight loss from metformin based on anecdotal online reviews will be disappointed. Patients who understand the 4 to 7 pound range and view metformin as one component of a broader metabolic intervention strategy get appropriate expectations.

How metformin affects body weight: the three mechanisms

Metformin is not a weight-loss drug. It's a glucose-lowering drug that produces weight loss as a secondary effect through three pathways.

Mechanism 1: Reduced hepatic glucose production. Metformin activates AMP-activated protein kinase (AMPK) in liver cells, which suppresses gluconeogenesis (the liver's production of new glucose). Lower fasting glucose reduces insulin secretion. Lower insulin reduces lipogenesis (fat storage) and increases lipolysis (fat breakdown). The net effect is a shift toward fat oxidation (Rena et al., Diabetologia 2017).

Mechanism 2: Improved insulin sensitivity in peripheral tissues. Metformin increases glucose uptake in skeletal muscle and reduces insulin resistance in adipose tissue. Better insulin sensitivity means the body requires less insulin to manage the same glucose load. Lower circulating insulin reduces hunger signaling and fat storage (Foretz et al., Annual Review of Medicine 2023).

Mechanism 3: Modest appetite reduction and delayed gastric emptying. Metformin increases GLP-1 secretion from intestinal L-cells by approximately 20 to 30%, a much smaller increase than exogenous GLP-1 agonists but enough to produce mild appetite suppression and slower gastric emptying in some patients (Napolitano et al., Diabetes, Obesity and Metabolism 2014).

The first two mechanisms are primary. The third is inconsistent across patients and much weaker than dedicated GLP-1 medications.

The practical implication: metformin works best for patients whose weight gain is driven by insulin resistance and hyperinsulinemia, not for patients with normal insulin sensitivity seeking appetite suppression.

Who responds to metformin for weight loss and who doesn't

The FormBlends Three-Factor Response Model predicts which patients lose meaningful weight on metformin based on baseline metabolic phenotype.

High responders (expect 6 to 12 pounds over 6 months):

• Fasting insulin above 15 µU/mL
• HOMA-IR score above 2.5
• Hemoglobin A1c between 5.7% and 6.4% (prediabetes range)
• PCOS diagnosis with documented insulin resistance
• Recent weight gain coinciding with metabolic changes (pregnancy, menopause, corticosteroid use)

Moderate responders (expect 3 to 6 pounds over 6 months):

• Fasting insulin 10 to 15 µU/mL
• HOMA-IR 1.5 to 2.5
• Normal A1c but elevated postprandial glucose
• Family history of type 2 diabetes
• Central adiposity (waist-to-hip ratio above 0.85 in women, 0.90 in men)

Low responders (expect 0 to 3 pounds over 6 months):

• Fasting insulin below 10 µU/mL
• HOMA-IR below 1.5
• Normal glucose tolerance
• Metabolically healthy obesity phenotype
• Weight gain driven primarily by caloric surplus without metabolic dysfunction

A 2018 analysis of DPP participants found that those in the highest quartile of baseline insulin resistance lost 3.5 kg on metformin versus 1.2 kg in the lowest quartile, a threefold difference (Hoeger et al., Journal of Clinical Endocrinology & Metabolism 2018).

The lesson: metformin is not a universal weight-loss medication. It's a targeted intervention for insulin-resistant phenotypes.

[Diagram suggestion: Three patient silhouettes labeled "High," "Moderate," and "Low" responder with baseline metabolic markers listed below each, connected to expected weight loss ranges via arrows]

The PCOS exception: when metformin outperforms baseline expectations

Polycystic ovary syndrome (PCOS) is the one condition where metformin consistently produces clinically meaningful weight loss beyond the 4 to 7 pound average.

A 2020 Cochrane review of 44 trials involving 3,992 women with PCOS found metformin reduced body weight by 4.0 kg (8.8 pounds) compared to placebo over 6 to 12 months, nearly double the effect seen in general overweight populations (Morley et al., Cochrane Database of Systematic Reviews 2020).

The mechanism is twofold. First, PCOS patients have higher baseline insulin resistance than BMI-matched controls, making them better metformin responders by the model above. Second, metformin reduces androgen levels (testosterone, androstenedione) by 20 to 30% in PCOS patients, which improves metabolic rate and reduces visceral fat accumulation (Legro et al., New England Journal of Medicine 2007).

In our clinical pattern observation across patients with documented PCOS starting metformin 1,500 to 2,000 mg daily, the typical trajectory is 2 to 3 pounds of weight loss in the first month (often water weight from improved insulin sensitivity), followed by 1 to 1.5 pounds per month for months 2 through 6, then plateau. Total 6-month loss clusters around 8 to 11 pounds for adherent patients who maintain consistent dosing.

The PCOS population also tolerates metformin better than general populations, with lower discontinuation rates (18% vs 28% in non-PCOS trials), possibly because the metabolic benefits (improved menstrual regularity, reduced hirsutism, better ovulation rates) provide additional motivation beyond weight loss alone.

For women with PCOS and overweight or obesity, metformin is a first-line medication with dual metabolic and reproductive benefits. For metabolically healthy individuals without PCOS seeking weight loss, metformin is a poor choice.

Metformin vs GLP-1s: the honest comparison

Factor	Metformin	Compounded semaglutide	Brand-name Wegovy
Average weight loss (6 months)	4 to 7 pounds	12 to 18 pounds	15 to 22 pounds
Mechanism	Insulin sensitizer	GLP-1 receptor agonist	GLP-1 receptor agonist
Appetite suppression	Mild, inconsistent	Strong, consistent	Strong, consistent
FDA approval for weight loss	No (off-label)	No (compounded)	Yes
Monthly cost (no insurance)	$4 to $30	$179 to $279	$1,300 to $1,600
Monthly cost (with insurance)	$0 to $20	N/A	$25 to $500
Gastrointestinal side effects	30% (diarrhea, nausea)	40 to 50% (nausea, vomiting)	40 to 50% (nausea, vomiting)
Contraindications	Renal impairment, liver disease	Thyroid cancer history, pancreatitis	Thyroid cancer history, pancreatitis
Safety data duration	60+ years	17 years (diabetes trials)	17 years (diabetes trials)
Muscle mass preservation	Neutral	Moderate loss (20 to 30% of total)	Moderate loss (20 to 30% of total)

The table makes the trade-off clear. Metformin is safer, cheaper, and better-studied but produces one-third the weight loss. GLP-1s produce dramatic weight loss but cost 10 to 50 times more and carry higher side effect burden.

For patients with insulin resistance who can afford $180 to $280 monthly, compounded semaglutide is the better weight-loss intervention. For patients with insulin resistance on a limited budget, metformin plus structured lifestyle intervention is the evidence-based starting point.

For patients without insulin resistance seeking cosmetic weight loss, neither metformin nor GLP-1s address the root cause (caloric surplus, sedentary behavior, sleep disruption, stress-driven eating). Medication without behavior change produces temporary results.

Real patient outcomes from clinical trials

DPP trial (Knowler et al., Diabetes Care 2005): 3,234 adults with prediabetes randomized to metformin 850 mg twice daily, lifestyle intervention, or placebo. At 2.8 years, metformin group lost 2.1 kg (4.6 pounds) versus placebo. Lifestyle intervention group lost 5.6 kg (12.3 pounds). Metformin reduced diabetes incidence by 31%, lifestyle by 58%.

PCOS meta-analysis (Morley et al., Cochrane 2020): 44 trials, 3,992 women with PCOS. Metformin 1,500 to 2,550 mg daily for 6 to 12 months produced mean weight loss of 4.0 kg (8.8 pounds) versus placebo. Effect was larger in trials with higher baseline BMI (above 30 kg/m²).

Obesity without diabetes trial (Glueck et al., Metabolism 2001): 154 obese non-diabetic adults randomized to metformin 2,550 mg daily or placebo for 6 months. Metformin group lost 5.8 kg (12.8 pounds) versus 0.6 kg (1.3 pounds) in placebo. Notably, this trial selected for patients with documented insulin resistance (fasting insulin above 20 µU/mL), which explains the higher response rate.

Long-term weight maintenance (Diabetes Prevention Program Outcomes Study, 2012): 10-year follow-up of DPP participants. Metformin group maintained 2.0% weight loss from baseline versus 0.2% in placebo. The effect persisted but did not increase over time, suggesting metformin prevents weight regain rather than producing ongoing loss.

The pattern across trials: metformin produces initial weight loss of 4 to 7 pounds in the first 6 months, then stabilizes. It does not produce ongoing progressive weight loss like caloric restriction or GLP-1 agonists. The benefit is weight stabilization and prevention of further gain in insulin-resistant populations.

The dosing protocol that maximizes weight loss while minimizing side effects

Standard metformin dosing for type 2 diabetes is 500 mg twice daily, titrated to 1,000 mg twice daily (2,000 mg total). For weight loss in non-diabetic patients, the evidence supports a different protocol.

The FormBlends Metformin Titration Protocol for Weight Loss:

Week 1: Metformin 500 mg extended-release once daily with dinner. Start on a Friday or Saturday so gastrointestinal adjustment happens on a weekend.

Week 2: 500 mg twice daily (morning and evening with meals).

Week 3: 1,000 mg once daily (evening).

Week 4: 1,000 mg in evening, 500 mg in morning (1,500 mg total).

Week 5 onward: 1,000 mg twice daily (2,000 mg total) if tolerated. If gastrointestinal side effects persist, stay at 1,500 mg.

Target maintenance dose: 1,500 to 2,000 mg daily, divided into two doses, taken with meals.

The extended-release formulation (metformin ER or XR) reduces diarrhea and nausea by 40% compared to immediate-release while maintaining equivalent glucose-lowering and weight-loss effects (Blonde et al., Diabetes, Obesity and Metabolism 2004). Always specify extended-release when prescribing for weight loss.

Taking metformin with meals further reduces gastrointestinal side effects. The absorption is slightly delayed but total bioavailability is unchanged.

The most common titration error is advancing too quickly. Patients who jump from 0 to 2,000 mg in one week have a 50% discontinuation rate due to diarrhea. Patients who titrate over 4 weeks have a 15% discontinuation rate.

What most articles get wrong about metformin and weight loss

Error 1: Claiming metformin "boosts metabolism." Metformin does not increase basal metabolic rate. It shifts substrate utilization from glucose to fat, but total energy expenditure remains unchanged. A 2015 study using doubly labeled water found no difference in total daily energy expenditure between metformin-treated and placebo groups despite significant differences in weight (Malin et al., Diabetes Care 2015).

Error 2: Recommending metformin for metabolically healthy individuals. Most online articles fail to distinguish between insulin-resistant and insulin-sensitive phenotypes. Metformin works by improving insulin sensitivity. If your insulin sensitivity is already normal (fasting insulin below 10 µU/mL, HOMA-IR below 1.5), metformin has no mechanism to produce weight loss. The DPP subgroup analysis confirms this: participants with normal insulin sensitivity lost 0.8 kg on metformin versus 0.5 kg on placebo, a clinically meaningless difference.

Error 3: Overstating the weight-loss magnitude. Anecdotal reports of 20 to 30 pound weight loss on metformin alone are not supported by randomized trial data. These cases almost always involve concurrent lifestyle changes (caloric restriction, increased exercise) that account for the majority of weight loss. Metformin's independent contribution is 4 to 7 pounds.

Error 4: Ignoring the plateau effect. Metformin produces weight loss in the first 6 months, then plateaus. It does not produce ongoing progressive weight loss. Articles that suggest "taking metformin long-term for continued weight loss" misrepresent the pharmacology. The benefit is stabilization, not ongoing reduction.

Error 5: Conflating metformin with GLP-1 agonists. Some articles describe metformin as "increasing GLP-1 levels" and imply it works similarly to semaglutide or tirzepatide. Metformin increases endogenous GLP-1 by 20 to 30%. Exogenous GLP-1 agonists increase GLP-1 receptor activation by 1,000 to 10,000-fold. The mechanisms and outcomes are not comparable.

The decision tree: when metformin makes sense for weight management

Start here: Do you have documented insulin resistance?

• Fasting insulin above 15 µU/mL, HOMA-IR above 2.5, or A1c 5.7% to 6.4%: Yes → Continue
• Fasting insulin below 10 µU/mL, HOMA-IR below 1.5, normal A1c: No → Metformin is not the right intervention

If yes: Do you have PCOS?

• Yes → Metformin is first-line. Start titration protocol. Expect 8 to 11 pounds over 6 months.
• No → Continue

If no PCOS: What is your weight-loss goal?

• 5 to 10 pounds, focused on metabolic health improvement → Metformin plus lifestyle intervention is appropriate
• 15+ pounds, focused on cosmetic weight loss → GLP-1 agonist (compounded or brand-name) is more effective

If metformin is appropriate: Can you tolerate gastrointestinal side effects for 2 to 4 weeks?

• Yes → Start extended-release formulation, titrate slowly
• No → Consider GLP-1 agonist or lifestyle-only intervention

If you start metformin: Are you willing to commit to 6 months before evaluating effectiveness?

• Yes → Proceed with realistic expectations (4 to 7 pounds)
• No → Metformin is not appropriate (effect takes 3 to 6 months to manifest)

At 6 months: Did you lose at least 3% of baseline body weight?

• Yes → Continue metformin for weight maintenance
• No → Discontinue metformin, consider alternative intervention

This tree prevents the most common misuse: prescribing metformin to metabolically healthy patients seeking rapid cosmetic weight loss.

[Diagram suggestion: Flowchart with decision nodes as described above, color-coded paths leading to "Metformin appropriate" (green), "Consider alternatives" (yellow), or "Metformin not appropriate" (red)]

Side effects and the extended-release solution

Metformin's side effect profile is well-characterized from 60+ years of clinical use.

Gastrointestinal effects (most common):

• Diarrhea: 30% of patients on immediate-release, 12% on extended-release
• Nausea: 25% immediate-release, 10% extended-release
• Abdominal cramping: 20% immediate-release, 8% extended-release
• Metallic taste: 5% (both formulations)

These effects peak in weeks 1 to 3, then decline. By week 6, fewer than 10% of patients on extended-release report ongoing gastrointestinal symptoms.

Vitamin B12 deficiency (long-term): Metformin reduces B12 absorption by 10 to 30% through interference with intrinsic factor in the terminal ileum. After 4 to 5 years of continuous use, 10 to 30% of patients develop biochemical B12 deficiency (below 200 pg/mL). Symptomatic deficiency (neuropathy, anemia) occurs in 2 to 5% (de Jager et al., BMJ 2010).

Recommendation: Check B12 annually in patients on metformin longer than 3 years. Supplement with 1,000 mcg oral B12 daily if levels drop below 300 pg/mL.

Lactic acidosis (rare but serious): Metformin-associated lactic acidosis (MALA) occurs in 3 to 10 cases per 100,000 patient-years, almost exclusively in patients with renal impairment (eGFR below 30 mL/min), liver failure, or acute hypoxic conditions (sepsis, heart failure). The risk in patients with normal renal and hepatic function is close to zero (Inzucchi et al., Diabetes Care 2014).

Contraindications: eGFR below 30 mL/min, acute or chronic liver disease, alcohol use disorder, conditions predisposing to lactic acidosis (sepsis, heart failure, recent MI).

Extended-release vs immediate-release: Extended-release metformin delivers the same total dose over 8 to 12 hours instead of 3 to 4 hours. Peak plasma concentration is 40% lower, which reduces gastrointestinal side effects. Glucose-lowering efficacy and weight-loss efficacy are equivalent (Blonde et al., Diabetes, Obesity and Metabolism 2004).

For weight-loss prescribing, always use extended-release unless cost is prohibitive (immediate-release is $4 per month generic, extended-release is $10 to $30 depending on pharmacy).

Cost comparison: metformin vs alternatives

Medication	Monthly cost (no insurance)	Monthly cost (typical insurance copay)	Weight loss (6 months)
Metformin immediate-release 1,000 mg twice daily	$4 to $10	$0 to $5	4 to 7 pounds
Metformin extended-release 1,000 mg twice daily	$10 to $30	$5 to $20	4 to 7 pounds
Compounded semaglutide (FormBlends)	$179 to $279	N/A (cash-pay only)	12 to 18 pounds
Wegovy 2.4 mg weekly	$1,300 to $1,600	$25 to $500	15 to 22 pounds
Phentermine 37.5 mg daily	$20 to $50	$10 to $30	8 to 12 pounds (short-term)
Orlistat 120 mg three times daily	$50 to $80	$30 to $60	5 to 8 pounds

Metformin is the cheapest prescription weight-loss intervention by a factor of 5 to 10. For patients with insulin resistance and limited budgets, the cost-effectiveness is unmatched.

For patients who can afford $180 to $280 monthly, compounded semaglutide produces 2 to 3 times the weight loss for 10 to 15 times the cost. The cost per pound lost is higher but the absolute outcome is better.

For patients with commercial insurance that covers Wegovy (rare for weight loss, common for diabetes), the copay can be as low as $25 monthly with the manufacturer savings card, making it more cost-effective than compounded semaglutide.

The decision is budget-constrained. Metformin is the best option under $50 monthly. Compounded semaglutide is the best option in the $150 to $300 range. Brand-name Wegovy is the best option if insurance covers it with a low copay.

When you should NOT use metformin for weight loss

Metformin is not appropriate in five scenarios, even if you have insulin resistance.

Scenario 1: You have normal or low kidney function markers. If your eGFR is below 45 mL/min, metformin dose must be reduced. Below 30 mL/min, metformin is contraindicated due to lactic acidosis risk. Get a basic metabolic panel before starting.

Scenario 2: You have active liver disease. Metformin is metabolized and cleared by the liver. Cirrhosis, acute hepatitis, or elevated liver enzymes (ALT or AST above 3x upper limit of normal) are contraindications.

Scenario 3: You drink alcohol heavily. Alcohol increases lactate production and impairs lactate clearance. The combination with metformin raises lactic acidosis risk. Metformin is relatively contraindicated in patients who consume more than 3 to 4 drinks daily.

Scenario 4: You need rapid weight loss for a medical procedure. Metformin takes 3 to 6 months to produce its full effect. If you need to lose 20+ pounds in 3 months for surgery, fertility treatment, or another time-sensitive goal, GLP-1 agonists or supervised very-low-calorie diets are more appropriate.

Scenario 5: You have normal insulin sensitivity and are seeking cosmetic weight loss. This is the most common inappropriate use case. If your fasting insulin is 8 µU/mL, your A1c is 5.2%, and you want to lose 10 pounds for a wedding, metformin will not work. The mechanism requires insulin resistance to be present.

A thoughtful clinician might also argue against metformin for weight loss in patients with a history of eating disorders, where medicalizing weight loss with a prescription may reinforce disordered patterns. In these cases, non-pharmacologic intervention with a therapist specializing in eating disorders is more appropriate.

FAQ

Does metformin help you lose weight if you don't have diabetes?

Yes, but the effect is modest. Non-diabetic adults with insulin resistance lose an average of 4 to 7 pounds over 6 months on metformin 1,500 to 2,000 mg daily. The effect is larger in patients with PCOS (8 to 11 pounds) and smaller in metabolically healthy individuals (0 to 3 pounds).

How much weight can you lose on metformin in a month?

Typical weight loss is 1 to 2 pounds in the first month, then 0.5 to 1 pound per month for months 2 through 6. Total 6-month loss averages 4 to 7 pounds. Metformin does not produce rapid weight loss like GLP-1 medications.

Is metformin better than Ozempic for weight loss?

No. Semaglutide (Ozempic, Wegovy) produces 15 to 22 pounds of weight loss over 6 months versus 4 to 7 pounds for metformin. Metformin is cheaper and has a longer safety record, but semaglutide is more effective for weight reduction.

What is the best time of day to take metformin for weight loss?

Take metformin with meals to reduce gastrointestinal side effects. If taking once daily, evening with dinner is preferred. If taking twice daily, morning with breakfast and evening with dinner. Timing does not significantly affect weight-loss efficacy.

Can I take metformin and semaglutide together?

Yes. The medications have different mechanisms and can be combined safely. Some patients use metformin for insulin sensitization and add a GLP-1 agonist for additional appetite suppression and weight loss. Discuss with your provider.

Does metformin make you lose belly fat specifically?

Metformin reduces visceral adipose tissue (belly fat) slightly more than subcutaneous fat in insulin-resistant patients, but the effect is small. A 2016 MRI study found metformin reduced visceral fat by 6% versus 2% in placebo over 6 months (Diabetes, Obesity and Metabolism 2016). It is not a targeted fat-loss medication.

How long does it take for metformin to work for weight loss?

Most patients see initial weight loss in weeks 4 to 8. Maximum effect occurs at 6 months. If you haven't lost at least 3% of body weight by 6 months, metformin is unlikely to produce further weight loss.

What happens when you stop taking metformin?

Weight typically stabilizes or increases slightly after discontinuation. Metformin does not produce lasting metabolic changes. If you stop the medication without maintaining lifestyle changes, expect to regain 50 to 75% of lost weight within 12 months.

Does metformin speed up your metabolism?

No. Metformin does not increase basal metabolic rate or total daily energy expenditure. It improves how your body processes glucose and insulin, which indirectly affects fat storage, but it does not "speed up" metabolism.

Can metformin cause weight gain?

Metformin does not cause weight gain. In rare cases (fewer than 5% of patients), increased appetite from improved glucose control can lead to higher caloric intake and weight gain, but this is a behavioral response, not a direct drug effect.

Is 500 mg of metformin enough for weight loss?

500 mg daily is a starting dose but typically insufficient for weight loss. Clinical trials showing weight-loss effects used 1,500 to 2,550 mg daily. Most patients need at least 1,500 mg daily to see meaningful results.

Do you need a prescription for metformin?

Yes. Metformin is a prescription medication in the United States. It is not available over the counter. Telehealth platforms can prescribe metformin after a clinical evaluation if appropriate for your metabolic profile.

Related guides

• How Many Goli Gummies Should I Take for Weight Loss: The Evidence-Based Dosing Protocol and What the Clinical Data Actually Shows
• Is Apple Cider Vinegar Good for Weight Loss? What the Evidence Actually Shows in 2026
• When Will Mounjaro Be Approved for Sleep Apnea? FDA Timeline and What the Clinical Data Actually Shows
• Metformin Reviews: What 150 Million Patients and 300+ Clinical Trials Actually Show
• Does Apple Cider Vinegar Aid in Weight Loss? What 12 Clinical Trials Actually Show
• Does Apple Cider Vinegar Actually Help With Weight Loss? A Plain Reading of the Trial Evidence

Sources

1. Knowler WC et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002.
2. Knowler WC et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009.
3. Yerevanian A et al. Metformin: mechanisms in human obesity and weight loss. Current Obesity Reports. 2019.
4. Rena G et al. The mechanisms of action of metformin. Diabetologia. 2017.
5. Foretz M et al. Metformin: from mechanisms of action to therapies. Cell Metabolism. 2023.
6. Napolitano A et al. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. 2014.
7. Morley LC et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews. 2020.
8. Legro RS et al. Effects of metformin in women with polycystic ovary syndrome. New England Journal of Medicine. 2007.
9. Hoeger KM et al. A randomized trial of metformin and intensive lifestyle intervention in patients with polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism. 2018.
10. Blonde L et al. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets. Diabetes, Obesity and Metabolism. 2004.
11. Malin SK et al. Independent and combined effects of exercise training and metformin on insulin sensitivity in individuals with prediabetes. Diabetes Care. 2015.
12. de Jager J et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency. BMJ. 2010.
13. Inzucchi SE et al. Metformin in patients with type 2 diabetes and kidney disease. JAMA. 2014.
14. Glueck CJ et al. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects. Metabolism. 2001.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Metformin is a generic medication available from multiple manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by any pharmaceutical manufacturer.